Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity

Cell

Volumn 169, Issue 6, 2017, Pages 1130-1141.e11

  Overacre Delgoffe, Abigail E ^a,b   Chikina, Maria ^a   Dadey, Rebekah E ^a   Yano, Hiroshi ^a   Brunazzi, Erin A ^a   Shayan, Gulidanna ^c   Horne, William ^d   Moskovitz, Jessica M ^a,c   Kolls, Jay K ^a,d   Sander, Cindy ^e   Shuai, Yongli ^e   Normolle, Daniel P ^e   Kirkwood, John M ^a,e   Ferris, Robert L ^a,c   Delgoffe, Greg M ^a,b,c   Bruno, Tullia C ^a,c   Workman, Creg J ^a,b   Vignali, Dario A A ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

cancer immunotherapy; interferon ; interferon receptor; neuropilin 1; PD 1; regulatory T cells; tumor immunology; tumor microenvironment

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 12; INTERLEUKIN 2; NEUROPILIN 1; STAT1 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL FATE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE DELETION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MALE; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; HEAD AND NECK TUMOR; IMMUNOLOGY; MELANOMA; METABOLISM; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-GAMMA; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEUROPILIN-1; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, INTERFERON; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 85019945399     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.05.005     Document Type: Article

References (66)

1. Battaglia, A., Buzzonetti, A., Monego, G., Peri, L., Ferrandina, G., Fanfani, F., Scambia, G., Fattorossi, A., Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 123 (2008), 129–138.
2. Battaglia, A., Buzzonetti, A., Baranello, C., Ferrandina, G., Martinelli, E., Fanfani, F., Scambia, G., Fattorossi, A., Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol. Immunother. 58 (2009), 1363–1373.
3. Battle, A., Mostafavi, S., Zhu, X., Potash, J.B., Weissman, M.M., McCormick, C., Haudenschild, C.D., Beckman, K.B., Shi, J., Mei, R., et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res. 24 (2014), 14–24.
4. Briggs, S.F., Reijo Pera, R.A., X chromosome inactivation: recent advances and a look forward. Curr. Opin. Genet. Dev. 28 (2014), 78–82.
5. Chaudhary, B., Elkord, E., Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert Opin. Ther. Targets 19 (2015), 147–161.
6. Chaudhary, B., Khaled, Y.S., Ammori, B.J., Elkord, E., Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol. Immunother. 63 (2014), 81–99.
7. Chaudhry, A., Rudensky, A.Y., Control of inflammation by integration of environmental cues by regulatory T cells. J. Clin. Invest. 123 (2013), 939–944.
8. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
9. Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A., Stewart, T.A., Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259 (1993), 1739–1742.
10. Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.R., et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146 (2011), 772–784.
11. Delgoffe, G.M., Woo, S.R., Turnis, M.E., Gravano, D.M., Guy, C., Overacre, A.E., Bettini, M.L., Vogel, P., Finkelstein, D., Bonnevier, J., et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501 (2013), 252–256.
12. Deligne, C., Metidji, A., Fridman, W.H., Teillaud, J.L., Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia 29 (2015), 947–957.
13. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
14. Dominguez-Villar, M., Baecher-Allan, C.M., Hafler, D.A., Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17 (2011), 673–675.
15. Drennan, S., Stafford, N.D., Greenman, J., Green, V.L., Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology 140 (2013), 335–343.
16. Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F., Campbell, D.J., Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119 (2012), 4430–4440.
17. Facciabene, A., Motz, G.T., Coukos, G., T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72 (2012), 2162–2171.
18. Fontenot, J.D., Gavin, M.A., Rudensky, A.Y., Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003), 330–336.
19. Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., Rudensky, A.Y., Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005), 329–341.
20. Galupa, R., Heard, E., X-chromosome inactivation: new insights into cis and trans regulation. Curr. Opin. Genet. Dev. 31 (2015), 57–66.
21. + regulatory t cells exhibit primary negative immunoregulation in sepsis. Mediators Inflamm., 2016, 2016, 7132158.
22. Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A.M., et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J. Exp. Med. 209 (2012), 2001–2016.
23. Hill, J.A., Feuerer, M., Tash, K., Haxhinasto, S., Perez, J., Melamed, R., Mathis, D., Benoist, C., Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27 (2007), 786–800.
24. + regulatory T cells. Immunol. Rev. 259 (2014), 159–172.
25. Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., Vilcek, J., Zinkernagel, R.M., Aguet, M., Immune response in mice that lack the interferon-gamma receptor. Science 259 (1993), 1742–1745.
26. Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., Fujii, H., Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9 (2003), 4404–4408.
27. Jackson, S.R., Berrien-Elliott, M., Yuan, J., Hsueh, E.C., Teague, R.M., Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype. PLoS ONE, 9, 2014, e110707.
28. Jacobs, J.F., Nierkens, S., Figdor, C.G., de Vries, I.J., Adema, G.J., Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol. 13 (2012), e32–e42.
29. Kim, J.M., Rasmussen, J.P., Rudensky, A.Y., Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8 (2007), 191–197.
30. Knol, A.C., Nguyen, J.M., Quéreux, G., Brocard, A., Khammari, A., Dréno, B., Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Exp. Dermatol. 20 (2011), 430–434.
31. Koch, M.A., Thomas, K.R., Perdue, N.R., Smigiel, K.S., Srivastava, S., Campbell, D.J., T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity 37 (2012), 501–510.
32. Koenecke, C., Lee, C.W., Thamm, K., Föhse, L., Schafferus, M., Mittrücker, H.W., Floess, S., Huehn, J., Ganser, A., Förster, R., Prinz, I., IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J. Immunol. 189 (2012), 2890–2896.
33. Law, C.W., Chen, Y., Shi, W., Smyth, G.K., voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol., 15, 2014, R29.
34. Lee, J.T., Bartolomei, M.S., X-inactivation, imprinting, and long noncoding RNAs in health and disease. Cell 152 (2013), 1308–1323.
35. Lee, S.H., Carrero, J.A., Uppaluri, R., White, J.M., Archambault, J.M., Lai, K.S., Chan, S.R., Sheehan, K.C., Unanue, E.R., Schreiber, R.D., Identifying the initiating events of anti-Listeria responses using mice with conditional loss of IFN-γ receptor subunit 1 (IFNGR1). J. Immunol. 191 (2013), 4223–4234.
36. Lee, J.H., Elly, C., Park, Y., Liu, Y.C., E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1α to maintain regulatory t cell stability and suppressive capacity. Immunity 42 (2015), 1062–1074.
37. Liao, Y., Smyth, G.K., Shi, W., featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30 (2014), 923–930.
38. Liu, C., Workman, C.J., Vignali, D.A., Targeting regulatory T cells in tumors. FEBS J. 283 (2016), 2731–2748.
39. McMurchy, A.N., Levings, M.K., Suppression assays with human T regulatory cells: a technical guide. Eur. J. Immunol. 42 (2012), 27–34.
40. Milpied, P., Renand, A., Bruneau, J., Mendes-da-Cruz, D.A., Jacquelin, S., Asnafi, V., Rubio, M.T., MacIntyre, E., Lepelletier, Y., Hermine, O., Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur. J. Immunol. 39 (2009), 1466–1471.
41. Miyara, M., Sakaguchi, S., Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13 (2007), 108–116.
42. Nishikawa, H., Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 127 (2010), 759–767.
43. Olalekan, S.A., Cao, Y., Hamel, K.M., Finnegan, A., B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur. J. Immunol. 45 (2015), 988–998.
44. Oldenhove, G., Bouladoux, N., Wohlfert, E.A., Hall, J.A., Chou, D., Dos Santos, L., O'Brien, S., Blank, R., Lamb, E., Natarajan, S., et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31 (2009), 772–786.
45. Overacre, A.E., Vignali, D.A., T(reg) stability: to be or not to be. Curr. Opin. Immunol. 39 (2016), 39–43.
46. Pandiyan, P., Zhu, J., Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells. Cytokine 76 (2015), 13–24.
47. Pearce, S.C., Introduction to Fisher (1925) Statistical Methods for Research Workers. Kotz, S., Johnson, N.L., (eds.) Breakthroughs in Statistics: Methodology and Distribution, 1992, Springer New York, 59–65.
48. Piechnik, A., Dmoszynska, A., Omiotek, M., Mlak, R., Kowal, M., Stilgenbauer, S., Bullinger, L., Giannopoulos, K., The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int. J. Cancer 133 (2013), 1489–1496.
49. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
50. Rubtsov, Y.P., Rasmussen, J.P., Chi, E.Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W.R. Jr., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28 (2008), 546–558.
51. Rubtsov, Y.P., Niec, R.E., Josefowicz, S., Li, L., Darce, J., Mathis, D., Benoist, C., Rudensky, A.Y., Stability of the regulatory T cell lineage in vivo. Science 329 (2010), 1667–1671.
52. Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22 (2016), 679–684.
53. Sakaguchi, S., Vignali, D.A., Rudensky, A.Y., Niec, R.E., Waldmann, H., The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 13 (2013), 461–467.
54. Sharma, M.D., Huang, L., Choi, J.H., Lee, E.J., Wilson, J.M., Lemos, H., Pan, F., Blazar, B.R., Pardoll, D.M., Mellor, A.L., et al. An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38 (2013), 998–1012.
55. St Rose, M.C., Taylor, R.A., Bandyopadhyay, S., Qui, H.Z., Hagymasi, A.T., Vella, A.T., Adler, A.J., CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol. Cell Biol. 91 (2013), 173–183.
56. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102 (2005), 15545–15550.
57. + regulatory T cells for early and late phases of murine sepsis. Immunology 146 (2015), 144–156.
58. Turnis, M.E., Sawant, D.V., Szymczak-Workman, A.L., Andrews, L.P., Delgoffe, G.M., Yano, H., Beres, A.J., Vogel, P., Workman, C.J., Vignali, D.A., Interleukin-35 limits anti-tumor immunity. Immunity 44 (2016), 316–329.
59. Vignali, D.A., Collison, L.W., Workman, C.J., How regulatory T cells work. Nat. Rev. Immunol. 8 (2008), 523–532.
60. Visperas, A., Shen, B., Min, B., γδ T cells restrain extrathymic development of Foxp3+-inducible regulatory T cells via IFN-γ. Eur. J. Immunol. 44 (2014), 2448–2456.
61. Workman, C.J., Collison, L.W., Bettini, M., Pillai, M.R., Rehg, J.E., Vignali, D.A., In vivo Treg suppression assays. Methods Mol. Biol. 707 (2011), 119–156.
62. Wu, D., Smyth, G.K., Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res., 40, 2012, e133.
63. Zhao, J., Zhao, J., Fett, C., Trandem, K., Fleming, E., Perlman, S., IFN-γ- and IL-10-expressing virus epitope-specific Foxp3(+) T reg cells in the central nervous system during encephalomyelitis. J. Exp. Med. 208 (2011), 1571–1577.
64. Zhao, J., Zhao, J., Perlman, S., Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS ONE, 7, 2012, e46241.
65. Zhou, X., Bailey-Bucktrout, S., Jeker, L.T., Bluestone, J.A., Plasticity of CD4(+) FoxP3(+) T cells. Curr. Opin. Immunol. 21 (2009), 281–285.
66. Zhou, X., Bailey-Bucktrout, S.L., Jeker, L.T., Penaranda, C., Martínez-Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., Bluestone, J.A., Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10 (2009), 1000–1007.